Jamie Dwyer
Last active: 4/21/2014

Profile

My clinical expertise centers around kidney disease (in general) but specifically diabetic kidney disease and other glomerular lesions, including glomerulonephritis. I have also developed expertise in the evaluation, management, and prevention of kidney stones (nephrolithiasis).  My clinical research has focused on these areas as well, particularly on the design, conduct, and analysis of large-scale randomized clinical trials (RCT) in nephrology and hypertension, particularly in delaying the progression of chronic kidney disease (CKD). I am the Co-Director of the Vanderbilt Nephrology Clinical Trials Center, a founding part of the Vanderbilt Center for the Study of Kidney Disease. Additionally, I am an Officer of the Collaborative Study Group (CSG), a international, non-profit organization dedicated to the exceptionally rigorous design and analysis and safe conduct of pilot and multinational, large-scale, pivotal RCTs in relevant therapeutic areas, including CKD, diabetic nephropathy, lupus, lupus nephritis, and end-stage renal disease.  My expertise centers around protocol design, medical monitoring, trial conduct, and safety.

My clinical research has focused on the design, conduct, and analysis of large-scale randomized clinical trials (RCT) in nephrology and hypertension, particularly in delaying the progression of chronic kidney disease (CKD). I am the Co-Director of the Vanderbilt Nephrology Clinical Trials Center, a founding part of the Vanderbilt Center for the Study of Kidney Disease. Additionally, I am an Officer of the Collaborative Study Group (CSG), a international, non-profit organization dedicated to the exceptionally rigorous design and analysis and safe conduct of pilot and multinational, large-scale, pivotal RCTs in relevant therapeutic areas, including CKD, diabetic nephropathy, lupus, lupus nephritis, and end-stage renal disease.  My expertise centers around protocol design, medical monitoring, trial conduct, and safety. I have participated on numerous Protocol Design, M&M, and DSMB committees. I have served as the Medical Monitor for multiple compounds and trials, detailed below. To support my expertise in safe conduct of trials, I currently serve as the Vice-Chair of my University’s Health Science’s Institutional Review Board. I have analyzed renal safety signals in non-renal clinical trials presented to the FDA.  Additionally, I am interested in investigating alternative, proximal outcomes in large RCTs in nephrology which will increase event rates, reduce follow-up time, and reduce sample sizes, in order to speed intervention development to delay the progression of CKD.  Finally, as part of this interest in endpoint analysis, I am interested in the measurement of renal function and its implications for the design and choice of endpoints in large RCTs.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. Dwyer JP, Greco BA, Umanath K, Packham D, Fox JW, Peterson R, Broome BR, Greene LE, Sika M, Lewis JB (2015) Nephron 129(1): 22-8
    › Primary publication · 25532068 (PubMed)
  2. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP, Collaborative Study Group (2015) Expert Rev Pharmacoecon Outcomes Res 15(3): 545-50
    › Primary publication · 25495878 (PubMed)
  3. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data. Sinsakul M, Rodby R, Umanath K, Niecestro R, Dwyer JP (2014) Expert Rev Clin Pharmacol 7(6): 705-10
    › Primary publication · 25242077 (PubMed)
  4. Does renal dysfunction and method of bridging support influence heart transplant graft survival? Haglund NA, Feurer ID, Dwyer JP, Stulak JM, DiSalvo TG, Keebler ME, Schlendorf KH, Wigger MA, Maltais S (2014) Ann Thorac Surg 98(3): 835-41
    › Primary publication · 25069689 (PubMed)
  5. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D (2014) Am J Kidney Dis 64(5): 714-22
    › Primary publication · 25064674 (PubMed)
  6. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study Group (2015) J Am Soc Nephrol 26(2): 493-503
    › Primary publication · 25060056 (PubMed) · PMC4310662 (PubMed Central)
  7. Guidelines and Straitjackets: blood pressure targets in the era of the Eighth Joint National Committee. Umanath K, Burgner A, Lewis JB, Dwyer JP (2014) Am J Kidney Dis 63(6): 895-9
    › Primary publication · 24721220 (PubMed)
  8. Optimizing blood pressure control in patients with nondiabetic glomerular disease. Umanath K, Lewis JB, Dwyer JP (2014) Adv Chronic Kidney Dis 21(2): 200-4
    › Primary publication · 24602469 (PubMed)
  9. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D (2014) Am J Kidney Dis 63(2): 244-50
    › Primary publication · 24210590 (PubMed)
  10. AKI in an HIV patient. Hartle PM, Carlo ME, Dwyer JP, Fogo AB (2013) J Am Soc Nephrol 24(8): 1204-8
    › Primary publication · 23559580 (PubMed) · PMC3736712 (PubMed Central)
  11. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013) Am J Kidney Dis 61(5): 759-66
    › Primary publication · 23369827 (PubMed)
  12. Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. Dwyer JP, Lewis JB (2013) Med Clin North Am 97(1): 53-8
    › Primary publication · 23290729 (PubMed)
  13. In-center thrombolysis for clotted AV access: a cohort review. Umanath K, Morrison RS, Christopher Wilbeck J, Schulman G, Bream P, Dwyer JP (2013) Semin Dial 26(1): 124-9
    › Primary publication · 22784240 (PubMed)
  14. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Group (2013) Hemodial Int 17(1): 67-74
    › Primary publication · 22702490 (PubMed)
  15. Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB (2012) Cardiorenal Med 2(1): 1-10
    › Primary publication · 22493597 (PubMed) · PMC3318932 (PubMed Central)
  16. Estimating baseline kidney function in hospitalized patients with impaired kidney function. Siew ED, Ikizler TA, Matheny ME, Shi Y, Schildcrout JS, Danciu I, Dwyer JP, Srichai M, Hung AM, Smith JP, Peterson JF (2012) Clin J Am Soc Nephrol 7(5): 712-9
    › Primary publication · 22422536 (PubMed) · PMC3338282 (PubMed Central)
  17. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ (2012) Am J Kidney Dis 59(1): 75-83
    › Primary publication · 22051245 (PubMed)
  18. Olmesartan to prevent the development of microalbuminuria: is it new? Is it true? Is it important? Dwyer JP, Lewis JB (2011) Am J Kidney Dis 58(5): 700-3
    › Primary publication · 21802806 (PubMed)
  19. Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Packham DK, Ivory SE, Reutens AT, Wolfe R, Rohde R, Lambers Heerspink H, Dwyer JP, Atkins RC, Lewis J, Collaborative Study Group (2011) Nephron Clin Pract 118(4): c331-8
    › Primary publication · 21293156 (PubMed)
  20. Evaluation of renal artery stenosis in dialysis patients. Dwyer JP, Greco BA, Lewis JB (2009) Semin Dial 22(5): 519-23
    › Primary publication · 19558627 (PubMed)
  21. High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. Bridges MD, St Amant BS, McNeil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM (2009) AJR Am J Roentgenol 192(6): 1538-43
    › Primary publication · 19457816 (PubMed)
  22. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC (2009) AIDS Read 19(3): 114-21
    › Primary publication · 19334328 (PubMed)
  23. Vicarious contrast excretion by the gallbladder in contrast nephropathy. Umana IE, Dwyer JP (2009) Kidney Int 75(4): 446
    › Primary publication · 19180157 (PubMed)
  24. The fluid craze. Lette F, Dwyer JP (2008) Lancet 372(9641): 782-4
    › Primary publication · 18774404 (PubMed)
  25. Interns' work hours. Dwyer JP, Cohen MD (2005) N Engl J Med 352(7): 726-8; author reply 726-8
    › Primary publication · 15719446 (PubMed)